Collectively, our results suggest that the development of inhibitors for the subunits of the eIF3 complex (EIF3B, EIF3D) may be a promising research avenue toward pharmaceutical intervention in BC especially in cases where EIF4E is apparently missing. Here, EIF4E is linked to breast cancer.